



## Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit

August 24, 2020

CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- [Cue Biopharma, Inc.](#) (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™, the Company's next generation Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) scaffold, at the [16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit](#). Neo-STAT biologics are designed for targeted modulation of tumor-specific T cells with enhanced antigen modularity.

### Presentation Details

**Title:** Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity

**Presenter:** Ahmet S. Vakkasoglu, Ph.D., senior scientist

**Date:** August 31-September 4, 2020

The poster highlights the engineering of the Neo-STAT platform, a scaffold with pocket-stabilized, peptide-free HLA molecules that enables enhanced antigen modularity through exogenous peptide loading. Compared to first generation scaffolds, the design of Neo-STAT improves the productivity and efficiency of scaffold production. Additionally, Neo-STAT biologics can incorporate diverse T cell epitopes, including peptides bearing post-translational modifications, peptide mixtures and peptides derived from tumor neo-antigens, thereby broadening the flexibility and therapeutic impact of the Immuno-STAT platform to target a wider spectrum of disease-associated epitopes.

"We are pleased to be presenting the Neo-STAT platform, which was developed to allow for the generation of therapeutic molecules incorporating diverse T cell epitopes," said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. "The Neo-STAT platform enables us to access a wider range of therapeutically relevant epitopes, including near-term applications in cancer immunotherapy with shared as well as personalized tumor antigens. In addition to cancer immunotherapy, we are also assessing the potential applications of Neo-STAT in infectious diseases, particularly against novel pathogens where immediate T cell responses could provide protective immunity before other prophylactic vaccination approaches are developed."

### About Immuno-STAT

Immuno-STAT™ biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient's body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients' T cells to be extracted, modified outside the body (ex vivo), and reinfused.

### About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit [www.cuebiopharma.com](http://www.cuebiopharma.com) and follow us on Twitter <https://twitter.com/CueBiopharma>.

### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, and our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including

negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Investor Contact**

George B. Zavoico, Ph.D.  
VP, Investor Relations & Corporate Development  
Cue Biopharma, Inc.  
[gzavoico@cuebio.com](mailto:gzavoico@cuebio.com)

**Media Contact**

Alison Chen  
LifeSci Communications  
[achen@lifescicomms.com](mailto:achen@lifescicomms.com)



Source: Cue Biopharma, Inc.